Cell death

EQS-News: DEFENCE’S ACCUTOX PUBLISHED IN THE PRESTIGIOUS JOURNAL OF TRANSLATIONAL MEDICINE ITS PEER STUDY WITH PRECLINICAL DATA ON ACCUTOX AS AN ANTI-CANCER MOLECULE

Retrieved on: 
Lunedì, Giugno 17, 2024
Neoplasm, Translational medicine, Cell death, DTC, Cancer, Immune system, Interview, Melanoma, CSO, Therapy, Immunogenic cell death, Lung, Business, Breast, FDA, Spacecraft, Journal of Translational Medicine, CTA, Health Canada, Breast cancer, Antibody, OTCQB, Vaccine

Despite the impressive pro-killing abilities of the parent molecule, some cancer cell lines exhibited resistance.

Key Points: 
  • Despite the impressive pro-killing abilities of the parent molecule, some cancer cell lines exhibited resistance.
  • This prompted us to test additional Accum® variants, which led to the identification of the AccuTOX® molecule.
  • "This study presents insights of how the unconjugated AccuTOX® molecule works.
  • More specifically, we demonstrate that AccuTOX® displays improved killing efficiency, triggers immunogenic cell death and production of toxic byproducts while inducing endosomal breaks.

Global Ferroptosis Targeting Therapy Market Opportunity & Clinical Trials Insight 2024, Featuring Kojin Therapeutics, MitoImmune Therapeutics, Prothegen, PTC Therapeutics, Sumitomo and Tharimmune - ResearchAndMarkets.com

Retrieved on: 
Giovedì, Giugno 6, 2024
Health, Pharmaceutical, Cell death, Patient, Sumitomo Pharma, SARS-CoV-2, Research, EMA, Infection, Lipoxygenase, Therapy, PTC, In•ter a•li•a, Safety, PTC Therapeutics, Nanotechnology, Disorder, Ferroptosis, COVID-19, Inflammation, FDA, Virus, Mitochondrial disease, Cancer, Viral, Drug development, Pharmaceutical industry

The "Global Ferroptosis Targeting Therapy Market Opportunity & Clinical Trials Insight 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Ferroptosis Targeting Therapy Market Opportunity & Clinical Trials Insight 2024" report has been added to ResearchAndMarkets.com's offering.
  • Presently, no ferroptosis targeting therapies have entered into the commercial global market, thereby, representing an opportunity for pharma companies to advance the realm of ferroptosis targeted therapy.
  • On that account, several pharma in addition to biotech companies across the globe, comprising MitoImmune Therapeutics, and PTC Therapeutics.
  • Global Ferroptosis Targeting Therapy Market Opportunity and Clinical Trials Insight 2024 Report Highlights:
    Clinical Trials Insight on Key Therapies in Trials: > 10 Therapies
    Ferroptosis Targeting Therapy Clinical Trials Insight by Company, Country, Indication and Phase
    Ferroptosis Candidates Granted FDA and EMA Designations: Orphan, Fast Track

Boston Pharmaceuticals Presents Data at EASL Congress 2024 Showing Treatment With Long-acting FGF21 Analogue, BOS-580, Improved Lipid Profiles in Patients with Phenotypic MASH

Retrieved on: 
Mercoledì, Giugno 5, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Ceramide, Congress, Cell death, Lipid, Triglyceride, Patient, Hepatology, Diglyceride, EASL, Risk, Lipid metabolism, Metabolomics, Biomarker, MASH, Oxidative stress, Inflammation, Medication, FGF21, Diagnosis, Classification, Biopsy, Pharmaceutical industry

The data will be presented at the European Association for the Study of the Liver (EASL) Congress 2024, held from June 5-8 in Milan, Italy.

Key Points: 
  • The data will be presented at the European Association for the Study of the Liver (EASL) Congress 2024, held from June 5-8 in Milan, Italy.
  • “Our analysis demonstrated that the circulating lipidome in phenotypic MASH patients is distinct compared to that seen in obese but otherwise healthy adults.
  • Treatment of these patients with BOS-580 over 12 weeks substantially improved patient lipid profiles and reduced MASEF scores, a novel composite biomarker to identify at-risk MASH patients,” said Sophie Kornowski, CEO of Boston Pharmaceuticals.
  • “These data continue to highlight BOS-580’s potential as a powerful once-monthly treatment for MASH.

Merck KGaA, Darmstadt, Germany’s Innovative Oncology Pipeline of DNA Damage Response Inhibitors and Antibody-Drug Conjugates Poised to Advance Cancer Treatment

Retrieved on: 
Lunedì, Giugno 3, 2024
Research, Medical Devices, Clinical Trials, Biotechnology, Health, Pharmaceutical, Other Science, Science, Oncology, ADP, ASCO, PARP1, Cancer, CEACAM5, Merck Serono, Ovarian cancer, Glioblastoma, ATR, Merck, AACR, Health care, GD2, Patient, Cell, NSCLC, PARP, Society, ADC, DNA, Merck Group, Cell death, Niraparib, Ataxia–telangiectasia, Colorectal cancer, Carcinoma, Clinical trial, Neuroblastoma, Development, Osteosarcoma, Cell membrane, Lung cancer, ATM, DDR, Neoplasm, Part, Antigen, Prevalence, Avelumab, Phase, Pharmaceutical industry

“The advancements in our strong early-stage clinical pipeline of ADCs created with our in-house platform and DDR inhibitors are grounded in encouraging data, particularly for M9140 and tuvusertib.

Key Points: 
  • “The advancements in our strong early-stage clinical pipeline of ADCs created with our in-house platform and DDR inhibitors are grounded in encouraging data, particularly for M9140 and tuvusertib.
  • At Merck KGaA, Darmstadt, Germany, we strive every day to improve the futures of people living with cancer.
  • Our research explores the full potential of promising mechanisms in cancer research, focused on synergistic approaches designed to hit cancer at its core.
  • Our vision is to create a world where more cancer patients will become cancer survivors.

Merck’s Innovative Oncology Pipeline of DNA Damage Response Inhibitors and Antibody-Drug Conjugates Poised to Advance Cancer Treatment

Retrieved on: 
Lunedì, Giugno 3, 2024
Biotechnology, Other Health, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Genetics, Science, Clinical Trials, ADP, Colorectal cancer, ASCO, PARP1, Cancer, CEACAM5, Ovarian cancer, Glioblastoma, ATR, AACR, Health care, GD2, Patient, Cell, NSCLC, PARP, Society, ADC, DNA, Cell death, Niraparib, Ataxia–telangiectasia, Carcinoma, Clinical trial, Neuroblastoma, Development, Osteosarcoma, Cell membrane, Lung cancer, ATM, Neoplasm, DDR, Part, Antigen, Prevalence, Avelumab, Phase, Pharmaceutical industry

“The advancements in our strong early-stage clinical pipeline of ADCs created with our in-house platform and DDR inhibitors are grounded in encouraging data, particularly for M9140 and tuvusertib.

Key Points: 
  • “The advancements in our strong early-stage clinical pipeline of ADCs created with our in-house platform and DDR inhibitors are grounded in encouraging data, particularly for M9140 and tuvusertib.
  • These findings complement data for the first-in-class tuvusertib and lartesertib combination first presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 in April.
  • Our research explores the full potential of promising mechanisms in cancer research, focused on synergistic approaches designed to hit cancer at its core.
  • Our vision is to create a world where more cancer patients will become cancer survivors.

Leads Biolabs is Proud to Announce its Participation in the 2024 ASCO Annual Meeting with One Oral Presentation and Two Posters.

Retrieved on: 
Lunedì, Maggio 13, 2024
Online, Cell death, Tislelizumab, National Medical Products Administration, Patient, TGF, Renal cell carcinoma, NMPA, Immunoglobulin G, NPC, Tumor microenvironment, FDA, IND, Safety, Immunity, Cisplatin, TNFR2, Gemcitabine, PD-1, Glomus tumor, Cancer, ASCO, Society, HCC, Hepatocellular carcinoma, Immunotherapy, PD-L1, CD137, Carcinoma, Study, CDE, Annual general meeting, RCC, Vaccine

NANJING, China, May 13, 2024 /PRNewswire/ -- The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting will be held in Chicago from May 31 to June 4, 2024.

Key Points: 
  • NANJING, China, May 13, 2024 /PRNewswire/ -- The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting will be held in Chicago from May 31 to June 4, 2024.
  • Leads Biolabs will present the exciting clinical data on its four innovative clinical programs at the ASCO meeting.
  • LBL-024 received IND approvals from FDA and NMPA on July 30, 2021 and September 9, 2021 respectively to conduct phase Ⅰ/Ⅱ clinical research.
  • Dr. Charles Cai, Chief Medical Officer of Leads Biolabs, said "Leads Biolabs will be presenting four clinical projects at 2024 ASCO.

LIXTE Biotechnology Co-Sponsoring International Scientific Conference on “Therapeutic Over-Activation in Cancer”

Retrieved on: 
Mercoledì, Maggio 8, 2024
Harvard University, NKI, Carcinogenesis, Cell death, Research, Netherlands Cancer Institute, Workshop, Pharmaceutical industry

PASADENA, CA, May 08, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced it is co-sponsoring an international scientific workshop on “Therapeutic Over-Activation in Cancer” at Harvard University’s Dana Farber Cancer Institute on May 9 and 10, 2024 in Boston, Massachusetts.

Key Points: 
  • (“LIXTE” or the “Company”) ( Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced it is co-sponsoring an international scientific workshop on “Therapeutic Over-Activation in Cancer” at Harvard University’s Dana Farber Cancer Institute on May 9 and 10, 2024 in Boston, Massachusetts.
  • This unconventional approach is based on the deliberate over-activation of oncogenic signaling in cancer cells as a therapeutic strategy using LIXTE’s lead compound, LB-100.
  • LIXTE is the only company that has a drug in clinical trials with demonstrated capacity to over-activate oncogenic signaling.
  • LIXTE currently has three ongoing clinical trials utilizing LB-100 to enhance various cancer therapies.

US Medical Innovations Secures FDA Clearance for Canady Helios Cold Plasma™ Ablation System

Retrieved on: 
Martedì, Maggio 7, 2024
Research, Robotics, Oncology, Medical Devices, Technology, Artificial Intelligence, Clinical Trials, Science, Surgery, Biotechnology, FDA, Health, Risk, Innovation system, Doctor of Philosophy, SMC, RNS, Sheba Medical Center, Medicine, RMC, Oncology nursing, Purdue University, Canady, ROS, Surgical oncology, Entrepreneurship, Plasma, Johns Hopkins University, Patient, Multi, Argon, Safety, George Washington University, Microsoft Access, Cell death, Survival, IDE, University of Massachusetts, Treatment, Multimedia, Reactive nitrogen species, Engineer, CHCP, University, Apoptosis, FACS, Field line, Airline, Rush University Medical Center, Reactive oxygen species, Nursing

US Medical Innovations, LLC (USMI) announced today it has received FDA 510k Clearance (K240297) for the Canady Helios Cold Plasma™ (CHCP) Ablation System for the ablation of soft tissue during surgery.

Key Points: 
  • US Medical Innovations, LLC (USMI) announced today it has received FDA 510k Clearance (K240297) for the Canady Helios Cold Plasma™ (CHCP) Ablation System for the ablation of soft tissue during surgery.
  • The CHCP system consists of the Canady Helios Cold Plasma XL-1000 CP Smart Electrosurgical Generator, Canady Helios Cold Plasma Ablators, Foot Pedal and Trolley Cart.
  • The Canady Helios Cold Plasma™ System introduces a novel approach to soft tissue ablation using plasma.
  • For more information on US Medical Innovation’s products and technology please visit: www.usmedinnovations.com .

 New Study Reveals Potential Treatment for Neurological Lyme Disease

Retrieved on: 
Venerdì, Aprile 19, 2024
FDA, Brain, FGFR, Cancer, Inflammation, DSM-IV codes, Cell death, Bacteria, Apoptosis, FGFR3, FGFR2, Doctor of Philosophy, Research, Pathology, Borrelia burgdorferi, Sleep, Therapy, Nervous system, Patient, Lyme disease, Neuroborreliosis, Peripheral nervous system, Memory, Central nervous system, FGFR1, Frontiers, Knowledge, Infection, Pharmaceutical industry

PORTOLA VALLEY, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- Bay Area Lyme Foundation , a leading sponsor of Lyme disease research in the US, recently announced publication of a laboratory study showing that fibroblast growth factor receptor (FGFR) inhibitors may be appropriate as anti-inflammatory supplementary treatment for neurological Lyme disease, for which there are no universally effective treatments.

Key Points: 
  • PORTOLA VALLEY, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- Bay Area Lyme Foundation , a leading sponsor of Lyme disease research in the US, recently announced publication of a laboratory study showing that fibroblast growth factor receptor (FGFR) inhibitors may be appropriate as anti-inflammatory supplementary treatment for neurological Lyme disease, for which there are no universally effective treatments.
  • “Our research shows a potential connection between neurological Lyme disease and several other neurological conditions, and this common pathway may explain why Lyme can be confused with many other conditions.
  • “Lyme neuroborreliosis, or neurological Lyme, causes the most disabling symptoms in Lyme disease, yet there has been relatively little study of the disease mechanisms caused by the infection.
  • There has long been a question about whether the persistent neurological symptoms of Lyme disease are caused by live bacteria or bacterial remnants.

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Retrieved on: 
Giovedì, Aprile 25, 2024
Cancer, NOAEL, Triple-negative breast cancer, Esophageal cancer, IC50, Cell death, Uterine cancer, Drug resistance, Docetaxel, IND, DNA, Patient, Metastasis, Genome, Clinical trial, No-observed-adverse-effect level, Ovarian cancer, Vaccine

SEOUL, South Korea, April 25, 2024 /PRNewswire/ -- Hyundai Bioscience announced on April 25th that its clinical development plan of oral "Niclosamide Metabolic Anticancer Drug" targeting cancer patients with intractable cancer caused by p53 gene mutations.

Key Points: 
  • SEOUL, South Korea, April 25, 2024 /PRNewswire/ -- Hyundai Bioscience announced on April 25th that its clinical development plan of oral "Niclosamide Metabolic Anticancer Drug" targeting cancer patients with intractable cancer caused by p53 gene mutations.
  • Mutations in the p53 gene occur in almost all cancer types and cause intractable cancers such cases found in ovarian cancer, uterine cancer, esophageal cancer, etc.
  • Niclosamide can induce cancer cell death by regulating cancer cell metabolic pathways and can resolve drug resistance and cancer cell metastasis  while minimizing side effects.
  • Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."